[ @entity282 therapy by transdermal XXXX ].

@entity1 @entity390 @entity391 @entity6882 @entity1576 @entity158 @entity282 @entity3575
INTRODUCTION: Several investigations have shown that constant rate infusions of opioids are highly effective in the provision of @entity282 relief. However, such treatment require intravenous access, the availability of infusion pumps and adequate monitoring system. We have studied a transdermal @entity3575 formulation (F-TTS, developed by ALZA Corporation, Palo Alto, USA) which should avoid these problems. METHODS: The study was performed in orthopaedic @entity1 scheduled for hip arthroplasty. 40 @entity1 were included consecutively in a double-blind parallel comparison of F-TTS (n = 20) and placebo (n = 20) patches. The patches were applied 0.5 hours prior to epidural anaesthesia and changed after 24 hours. F-TTS is designed to deliver @entity3575 at the same rate of 75 micrograms/h. For 36 hours blood samples, @entity158 scores, respiratory patterns and vital signs were collected frequently. @entity1 could have supplemental @entity6882 on demand (50 mg/2 h) if the @entity158 relief was inadequate. RESULTS: @entity3575 blood concentrations increased (verum) during the 24 hours period (removal) and decreased slightly after that. At the end of the investigation (36 h) @entity3575 concentration remained significantly elevated (about 60% of 24-hours value). F-TTS provided good @entity282 relief although 11 @entity1 (of 20) required supplemental @entity6882 . @entity1 with F-TTS, however had very little @entity6882 compared to @entity1 with placebo. Two @entity1 (one of each group) had to be eliminated from the study due to severe @entity1576 or inadequate @entity6882 requirement respectively. The incidence of other side effects such as @entity390 , @entity391 and micturition difficulties were similar in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
